Jacqueline Lehmann-Che
机构: professeur biologie moléculaire
每年引用次数
引用次数
引用: 6,214
H-指数: 41
I10-指数 : 62
出版物: 166
Les virus foamy, un modèle rétroviral original
N. Renault , M.-L. Giron , J. Lehmann-Che , A. Saïb
Virologie 10 ( 6) 443 -454
1
2006
Cancers du sein hormono-dépendants: quels biomarqueurs tissulaires utiles dans la prise en charge ?
J. Lehmann-Che
Bio Tribune Magazine 39 ( 1) 29 -34
2011
P-006 Prognostic value of TP53 gene mutations in higher-risk MDS treated with azacitidine (AZA)
C. Bally , L. Ades , A. Renneville , M.J. Mozziconacci
Leukemia Research 37
2013
P-023 Incidence and prognostic value of TP53 mutations in IPSS low and INT 1 (lower risk) MDS with del 5q
C. Bally , L. Ades , A. Renneville , C. Preudhomme
Leukemia Research 37
1
2013
Les patients long-survivants d’un glioblastome ne présentent que très rarement la mutation IDH
E. Mandonnet , A. Amelot , E. Mandonnet , P. De Cremoux
Neurochirurgie 60 ( 6) 330 -331
2014
Profil phénotypique des métastases cérébrales de cancer bronchique prises en charge à l’hôpital Lariboisière entre 2009 et 2014
A. Tauziède-Espariat , M. Polivka , L. Françoise , B. Poirot
Annales de Pathologie 35 ( 5) 467 -468
2015
Tumor Metabolism Assessed by FDG-PET/CT and Tumor Proliferation Assessed by Genomic Grade Index to Predict Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
David Groheux , L. Biard , J. Lehmann-Che , L. Teixeira
European Journal of Nuclear Medicine and Molecular Imaging 45 ( 8) 1279 -1288
19
2018
Clinical Subtype-Derived p53 Gene Signature Is Predictive of Prognosis and Response to Chemotherapy in ER-Positive but Not in ER-Negative Breast Cancers.
L. Pusztai , R. Rouzier , Y. Qi , J. Lehmann-Che
Cancer Research 69 6122 -6122
1
2009
Correlation between 18F Fluorodeoxyglucose (FDG) Uptake and Tumor Characteristics in Locally Advanced Breast Cancers.
M. Marty , J. Moretti , M. Espie , S. Giacchetti
Cancer Research 69 5010 -5010
2009
Challenging single- and multi-probesets gene expression signatures of pathological complete response to neoadjuvant chemotherapy in breast cancer: Experience of the REMAGUS 02 phase II trial
F. Valet , P. de Cremoux , F. Spyratos , N. Servant
The Breast 22 ( 6) 1052 -1059
9
2013
Abstract P5-10-22: Dose Dense Adjuvant Chemotherapy in Breast Cancer Patients with Five or More Nodes Involved: Results of a French Cohort with Long Term Follow-Up
CC Cuvier , FF Hocine , AS Hamy , SS Giacchetti
Cancer Research 70
2010
Dose Dense Adjuvant Chemotherapy in Breast Cancer Patients with Five or More Nodes Involved: Results of a French Cohort with Long Term Follow-Up
CC Cuvier , FF Hocine , AS Hamy , SS Giacchetti
CANCER RESEARCH 70
2010
Clock genes expression in breast cancers (BC) from patients (pts) treated with neoadjuvant chemotherapy (NAC) in a randomized multicenter phase II trial.
Sylvie Giacchetti , Ida Iurisci , Guillaume Meurice , Patricia de Cremoux
Journal of Clinical Oncology 32
2014
Prognostic value of PIK3CA mutations in HER2-positive early stage breast cancer: A French cohort study.
Florence Coussy , Jacqueline Lehmann- Che , Alice Sanna , Sylvie Giacchetti
Journal of Clinical Oncology 33
2015
Abstract P1-14-08: Prediction of pathological response (pCR) to neoadjuvant dose dense and intense cyclophosphamide and anthracycline in a prospective series of triple negative locally advanced breast cancers (TNLABC)
S Giacchetti , A De Roquancourt , D Groheux , P Piron
Cancer Research 76
2016
Early stages of HIV replication: how to hijack cellular functions for a successful infection.
Ali Saïb , Jacqueline Lehmann-Che
Aids Reviews 6 ( 4) 199 -207
19
2004
DNA arrays predictive markers of chemosensitivity to epirubicin-cyclophosphamide (EC) then docetaxel (ECD) primary chemotherapy for localized breast cancer
Sabrina Carpentier , Fabien Valet , Charles Decraene , Frederique Spyratos
Cancer Research 68 3620 -3620
2008
Early prediction of response to neoadjuvant chemotherapy in luminal breast cancer using total lesion glycolysis measured on 18F-FDG PET images: A prospective validation study
Patricia de Cremoux , Dimitris Visvikis , Antoine Martineau , Mathieu Hatt
Society of Nuclear Medicine Annual Meeting Abstracts 54 169
2013
Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM).
Sylvie Chevret , Aspasia Stamatoullas , Fatiha Chermat , Bruno Quesnel
Journal of Clinical Oncology 39 ( 14) 1575 -1583
8
2021
NUT Is a Specific Immunohistochemical Marker for the Diagnosis of YAP1-NUTM1-rearranged Cutaneous Poroid Neoplasms.
Amélie Osio , Brigitte Balme , Eric Frouin , Brigitte Poirot
The American Journal of Surgical Pathology
2021